Stock screenerAll disclosures →
EDGAR →
ANRO
Conviction 100HealthcareScan · Thu, Jun 25, 2026Shooting star
ANRO$25.25+1.36%
ResistanceSupportVol 14Vol MA14 423.87K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price25.25
Change+1.36%
Gap+0.04%
Rel volume2.75×
Avg volume386.57K
Avg $ vol8.29M
SMA 2021.11
SMA 5022.89
SMA 20016.75
Price vs 50+10.29%
Price vs 200+50.71%
MA stackbullish
50/200 cross—
Supertrendup · 20.24
RSI (14)66
MACD hist0.68
MACD cross—
Stoch %K / %D85 / 83
ADX (14)26
+DI / −DI27 / 8
RSI divergence—
MACD divergence—
ATR %+6.92%
ADR %7.79%
52w high27.72
52w low2.20
From 52w high-8.91%
Above 52w low+1047.73%
New 52w highNo
SqueezeOff
Bollinger width38.69%
%B1.01
Donchian pos84.78%
Donchian high26.57
Donchian low17.90
AVWAP (52w high)22.51
vs AVWAP high+12.16%
AVWAP (52w low)11.54
vs AVWAP low+118.78%
OBV trendUp
Chaikin MF (20)-0.13
Today vs 20d2.75×
Avg vol (14d)423.87K
Avg vol (20d)386.57K
Avg $ vol (20d)8.29M
Market cap886.12M
RS 3m (vs SPY)+11.12%
RS 6m (vs SPY)+16.94%
RS line new highNo
Trend template8/8
Technical rank90.3
1 week+15.88%
1 month+19.90%
3 months+22.16%
6 months+26.00%
1 year+910.00%
YTD+52.20%
P/E-14.01
P/B3.64
P/S—
P/FCF-17.11
EPS-2.19
Div yield—
ROE-25.98%
ROA-22.89%
Debt/Eq0.07
Current20.52
EV/EBITDA-9.69
Gross margin—
Net margin—
Rev growth—
EPS growth-2.94%
Price target34.78
Target upside37.74%
Analyst ratingBuy
Institutional81.05%
Ent. value638.38M
Revenue—
Net income-26.24M
Gross profit—
Free cash flow-51.79M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNYSE
Shares out35.09M
Employees68
ListedFri, Feb 2, 2024
Free float23.95M
Float %75.0%
Short interest1.69M
Days to cover5.5d
Short volume62.3%
Squeeze score69 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.80 vs −$0.56
Last surprise-42.9% miss
Setup gradeA+
Conviction100 / 100
Pattern quality—
Tech rank90.3 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmShooting star
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in ANRO
No recent disclosed trades by Congress in ANRO. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ANRO · 6 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Miller Andrew Craig Director · Stock Option (right to buy) · 2026-05-27 | Grant | 26K | $0 | 2026-05-27 | 2026-05-29 |
Etkin Amit PRESIDENT AND CEO · Common Stock · 2026-05-14 | Gift | 400K | $0 | 2026-05-14 | 2026-05-15 |
Cox Christopher Nixon Director · Stock Option (right to buy) · 2026-05-12 | Grant | 10.96K | $0 | 2026-05-12 | 2026-05-14 |
Sanchez Ramiro Director · Stock Option (right to buy) · 2026-05-12 | Grant | 10.96K | $0 | 2026-05-12 | 2026-05-14 |
Manji Husseini Director · Stock Option (right to buy) · 2026-05-12 | Grant | 10.96K | $0 | 2026-05-12 | 2026-05-14 |
Dreyfus Andrew Director · Stock Option (right to buy) · 2026-05-12 | Grant | 10.96K | $0 | 2026-05-12 | 2026-05-14 |
York Gwill Director · Stock Option (right to buy) · 2026-05-12 | Grant | 10.96K | $0 | 2026-05-12 | 2026-05-14 |
SEC filings
EDGAR filings in ANRO
No recent SEC filings on file for ANRO.
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.